Actively Recruiting

Phase 4
Age: 18Years - 80Years
All Genders
NCT06471231

Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock

Led by Azienda Usl di Bologna · Updated on 2024-06-24

264

Participants Needed

1

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The aim of the present study is to verify whether the earlier association of vasopressin and norepinephrine, in patients in septic shock, determines variations in terms of use of renal function replacement techniques in the first 7 days of hospitalization in Intensive Care, compared to patients in whom vasopressin is added only when norepinephrine reaches a higher dose.

CONDITIONS

Official Title

Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients suffering from septic shock hospitalized in an intensive care setting
  • Patients aged over 18 years and under 80 years
  • Patients within 24 hours of clinical diagnosis of septic shock
  • Patients requiring norepinephrine dosage equal to or greater than 0.25 mcg/kg/min according to ideal body weight within 24 hours
  • Patients capable of expressing informed consent to treatment
Not Eligible

You will not qualify if you...

  • Patients who do not consent to participate or to the processing of personal data
  • Patients under 18 years or over 80 years of age
  • Patients who died within the first 24 hours of ICU admission
  • Patients requiring norepinephrine dosage lower than 0.25 mcg/kg/min in first 24 hours of ICU stay
  • Patients with recent acute coronary syndrome within previous 7 days
  • Patients allergic or intolerant to study drugs or their components
  • Pregnant patients
  • Breastfeeding individuals
  • Patients needing urgent dialysis within 24 hours of ICU admission
  • Patients with end-stage renal failure or on dialysis (CKD stages 4 and 5, glomerular filtration < 30 ml/min)
  • Patients with a single kidney
  • Patients with bilateral renal hypoplasia
  • Patients who have had a kidney transplant
  • Patients undergoing haemoperfusion with adsorbent cartridge for bacterial endotoxin

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Azienda Unità Sanitaria Locale

Bologna, Italy, 40100

Actively Recruiting

Loading map...

Research Team

L

Lorenzo Giuntoli, Md

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here